[Featured Stock] Binex Rises on Expectations of 'Metomin' COVID-19 Treatment Effectiveness

[Asia Economy Reporter Hyunseok Yoo] Bionex is showing strong performance. It appears that the news expecting Metomin, a type 2 diabetes treatment solution, to have therapeutic effects against the novel coronavirus infection (COVID-19) has influenced this trend.

As of 1:54 PM on the 24th, Bionex was trading at 8,390 KRW, up 2.57% (210 KRW) compared to the previous trading day.

According to foreign media including The New York Times on the 22nd (local time), 69 drugs and experimental chemicals are expected to be effective in treating COVID-19.

The research team behind this study ultimately identified 24 drugs approved by the FDA for treating diseases that appear unrelated on the surface, such as cancer, Parkinson's disease, and hypertension. Unexpected candidates such as haloperidol, used for treating schizophrenia, and Metomin, taken by people with type 2 diabetes, were also included on the list.

This content was produced with the assistance of AI translation services.